Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 – – Dosed first patient in Phase 2 EQUINOX-HFpEF...
Covered in this story
Call it yourself
No calls on $HCM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on HUTCHMED →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.